Abstract
At an interim meeting on August 13, 2014, just in time for the upcoming respiratory season, CDC's Advisory Committee on Immunization Practices (ACIP) voted 13 to 2 to recommend the pneumococcal conjugate vaccine PCV13 (Prevnar 13 - Pfizer) for adults aged 65 years and older. The committee had delayed discussion and a vote at its June meeting to gather more information on the use of PCV13 in this patient population (for details, see page 21 of the August issue).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
